tradingkey.logo

Cogent Biosciences slips after upsized $200 mln equity offering

ReutersJul 9, 2025 10:28 AM

Shares of Cogent Biosciences COGT.O down 2.1% to $9.57 on light premarket volume after overnight follow-on pirced

Waltham, Massachusetts -based firm late Tues announced pricing ~22.2 mln shares at $9 for $200 mln gross proceeds

Deal size boosted from $ 150 mln, priced at 8% discount to last sale

Co plans to use net proceeds for continued development, regulatory and commercial preparation activities relating to bezuclastinib and other product candidates, among other purposes

COGT shares on Mon surged 23% to $9.35 after co said bezuclastinib showed statistically significant reduction in symptoms in patients with mastocytosis, a type of blood disorder, and that it expects to file a marketing application for the treatment by the end of 2025

JP Morgan, Leerink and Guggenheim are jt bookrunners for the offering

Through Tues close, shares up 25% YTD

9 of 12 analysts rate COGT "strong buy" or "buy", rest rate "hold" and median PT is $17.50 - LSEG data

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI